Recent clinical data suggest that fluconazole at daily doses of 200 to 400 mg for at least 6 months is moderately effective therapy for non-life-threatening blastomycosis. To examine the usefulness of higher doses of fluconazole therapy for this disorder, we conducted a multicenter, randomized, open-label study to determine the efficacy and safety of two different daily doses of fluconazole (400 and 800 mg) in the treatment of non-life-threatening blastomycosis. Of 39 patients evaluable for efficacy analysis, 34 (87%) were successfully treated, including 89% and 85% of patients who received 400 and 800 mg, respectively. Five (83%) of six patients for whom prior antifungal therapy had failed were successfully treated. The mean duration of therapy was 8.9 months for successfully treated patients. Nineteen patients (48%) reported adverse events, although most were minor. We conclude that fluconazole at daily doses of 400 to 800 mg for at least 6 months is effective therapy for non-life-threatening blastomycosis.
The availability of oral azole antifungal compounds has pro-Fluconazole, an oral and intravenous triazole approved by the U.S. Food and Drug Administration in 1990, has broad vided safer and more convenient therapy for most cases of blastomycosis, a systemic infection caused by the thermally antifungal activity and is approved for the treatment of mucosal and systemic candidiasis and cryptococcal meningitis. In addi-dimorphic fungus Blastomyces dermatitidis. At present, two azole compounds, ketoconazole and itraconazole, are approved tion, the compound has demonstrated activity in vitro and in vivo in animal models [6 -9] against several endemic fungi, for the treatment of blastomycosis. While amphotericin B remains the drug of choice for the treatment of severe or life-including B. dermatitidis. A recently reported pilot study of fluconazole for the treatment of non-life-threatening, non-CNS threatening disease, ketoconazole and itraconazole have largely replaced amphotericin B as therapy for mild to moderate forms blastomycosis in adults [10] demonstrated that the agent was reasonably efficacious when it was given at daily doses of 200 of the disease because of lesser toxicity, oral administration, and proven efficacy [1 -4] . Although there are no comparative to 400 mg for at least 6 months; overall, 65% of 23 patients had a successful outcome. Because of the encouraging results trials between the two azoles (or between the azoles and amphotericin B) for the treatment of blastomycosis, itraconazole of that study, a trial using higher daily doses of fluconazole (400 and 800 mg) was developed. While this study was not appears to be as effective as amphotericin B and somewhat more effective than ketoconazole as therapy for patients with powered to make comparisons between these two regimens, the efficacy estimates are necessary to design further phase 3 non-life-threatening disease. In addition, itraconazole is generally better tolerated than ketoconazole; thus, it has emerged as studies. The results of this trial, which was conducted by the National Institute of Allergy and Infectious Diseases Mycoses the oral azole of choice for the treatment of most patients with blastomycosis [3 -5] .
Study Group and Pfizer (New York), are presented herein. months and monthly thereafter), and at each posttreatment evaluation, each patient was examined, and symptoms and signs were recorded. Pretreatment laboratory evaluation included the Criteria for Study Entry following: determination of complete blood cell count with To be eligible for enrollment in the study, patients were differential cell count, platelet count, erythrocyte sedimentation required to have culture-proven or histopathologic evidence of rate, prothrombin time, partial thromboplastin time, blood urea blastomycosis. All patients with proven or presumptive blastonitrogen level, and serum creatinine level; liver function tests; mycosis were considered for the study but were excluded from routine urinalysis; and fungal culture of specimens from any enrollment if they had life-threatening or suspected CNS blasinvolved site. Chest radiography and other radiological imaging tomycosis or had only acute, self-limited pulmonary blastomystudies were performed as indicated by clinical findings. cosis (defined as a mild clinical illness characterized by sponta-At each clinic visit during therapy, all pretreatment laboraneous clinical and radiographic resolution). Other patients who tory tests were repeated. Cultures of specimens from any posiwere excluded from enrollment were those determined to be tive site(s) were repeated at monthly intervals until the culture HIV-positive, persons younger than 12 years of age, pregnant became negative or the lesion disappeared. Invasive procewomen, nursing mothers, and patients with significant abnordures, such as bone or lung biopsies, were generally not remalities of liver function (defined as levels of serum bilirubin, peated unless they were deemed clinically necessary. Approalkaline phosphatase, or aspartate aminotransferase that were priate radiographic studies were repeated at monthly intervals greater than five times the upper limit of normal). and as clinically indicated. Patients were evaluated at 3, 6, and In addition, patients were excluded from the study if they 12 months after therapy, and laboratory studies were repeated had received systemic antifungal therapy with amphotericin B, only if the results were originally abnormal or if clinically ketoconazole, or itraconazole for a previously untreated disease indicated. for ú3 days. Patients with persistent or relapsing disease following unsuccessful therapy had to have evidence of active Clinical Evaluation disease and culture-positive B. dermatitidis infection to be eligible for the study.
Patients and Methods
Case report forms detailing symptoms, signs, treatment regimen, compliance, clinical course, laboratory test results, drug toxicities, and response evaluations were completed for all pa-Treatment Regimen tients. Data from these forms were processed by Pfizer and were analyzed by the Mycoses Study Group Biostatistics Unit. Once a patient was determined to have met criteria for entry in the study and written informed consent was obtained, the Clinical responses were determined on the basis of symptoms and signs, results of roentgenography and scanning, and results patient was assigned a study number and was randomized to receive therapy with either 400 or 800 mg of fluconazole daily. of cultures before, during, and after therapy. Response to therapy was classified as either success or failure. Success was All patients received oral fluconazole treatment, and no other systemic antifungal therapy was allowed during the treatment defined as follows: cured -the patient had received therapy for at least 1 month, the symptoms and signs of infection had period. Reduction of the fluconazole dose was allowed for patients with reduced renal function according to recommended decreased by at least 75%, radiographic studies or scanning showed at least a 75% reduction in the size of the lesion(s), guidelines [11] . The treatment regimen was continued for a minimum of 3 months unless there was evidence of progressive and cultures were negative during the final month of therapy and during follow-up; or improved -the signs and symptoms blastomycosis or drug toxicity, at which time fluconazole therapy could be discontinued. of infection decreased by at least 25% but õ75%, and cultures were negative during the final month of therapy. Failure was For patients who were randomized to receive therapy with the lower dose of fluconazole, the daily dose could be increased defined as follows: progression of disease -any lesion present at the onset of therapy that enlarged or progressed, or a new to 600 or 800 mg if the investigator believed that the patient was not having an adequate response to the lower dose after lesion developed after the initial 4 weeks of therapy; persistence of disease -signs and symptoms of disease did not decrease at least 1 month of therapy. Patients who responded to therapy and experienced no drug toxicity could continue to receive by at least 25%, radiography or scanning showed no evidence of reduction in the size of the lesion(s), and/or cultures were fluconazole therapy for up to 24 months at the discretion of the investigator. Patients who in the opinion of the investigator positive during the final month of therapy; relapse -clinical, radiographic, or culture evidence of recurrent infection that did not have improved conditions or had disease progression were removed from the study, and their treatments were consid-developed after stopping fluconazole therapy for a patient who had met criteria for success at the end of therapy; drug ered failures (see below under Clinical Evaluation). Compliance was determined by pill counts.
toxicity -an adverse effect that necessitated stopping therapy (20 limited to the lungs in 15 of these patients, while the remaining patients) of fluconazole daily. One patient who received 400 19 had extrapulmonary involvement. The median duration of mg of fluconazole therapy daily was ineligible for study betherapy for successfully treated patients was 8.0 months (mean, cause the diagnosis of blastomycosis was not documented; this 8.9 months; range, 2 -24 months). Six patients' doses were patient is not included in the efficacy analysis, but the data on changed after they had received the randomized dose. The toxicity for this patient are included. All patients initially redaily dose was increased for five of the patients randomized ceived their randomly assigned doses. The demographics and to receive 400 mg (600 mg, one patient; 800 mg, four patients) clinical characteristics of the 39 evaluable patients are demonbecause of an inadequate clinical response. Four of these pastrated in table 1. Eleven patients (28%) had at least one sigtients were successfully treated with the increased daily dose nificant underlying condition. Six patients (15%) had received of fluconazole. The dose for one patient randomized to receive prior antifungal therapy with amphotericin B and/or ketoconatherapy with 800 mg of fluconazole daily was reduced because zole and had either relapsed while not receiving therapy (four of the development of a rash. The rash disappeared when the patients) or had persistent disease while receiving therapy (two daily dose was lowered to 400 mg, and the patient was successpatients).
fully treated.
The clinical manifestations of blastomycosis in these patients
Three patients died of unrelated illnesses during treatment varied broadly. Seventeen patients (44%) had disease limited for blastomycosis. One patient with underlying dermatomyoto the lung, 13 (33%) had only extrapulmonary involvement, sitis who was receiving chronic glucocorticoid therapy died and 9 (23%) had both pulmonary and extrapulmonary disease. of overwhelming staphylococcal pneumonia 5 months after Extrapulmonary sites included skin and subcutaneous tissue beginning therapy with 400 mg of fluconazole daily. Another (18 patients), bone (4), soft tissue (4), larynx (1), and prostate patient died of a myocardial infarction 2 months into therapy (1). Thirty-six patients had culture-positive B. dermatitidis inwith 800 mg of fluconazole daily. A third patient with underlyfection, and three had histopathologic evidence of blastomycoing congestive heart failure and chronic obstructive lung dissis with a clinically compatible illness. ease died of a massive pulmonary embolus 2 months after starting therapy with 400 mg of fluconazole daily. All three patients were being treated for uncomplicated pulmonary blas- disease had persistent blastomycosis despite therapy with 800 mg of fluconazole daily for 7 months, but this patient was noncompliant with therapy. This patient's condition improved who reported adverse events, although almost twice as many with itraconazole treatment. The second patient had persistent adverse events were reported by patients receiving 800 mg cutaneous disease after receiving therapy with 800 mg of fludaily than by those receiving 400 mg daily. conazole daily for 4 months. Refusing additional antifungal Nausea, vomiting, indigestion, and anorexia were the most therapy, the patient underwent surgical excision of the skin commonly reported toxicities, occurring in 25% of patients. lesion, and it did not recur. The third patient had extensive Reversible alopecia was reported by nine patients (23%), was pulmonary disease and developed worsening pulmonary more common in higher dose recipients (seven patients) than involvement with extensive cutaneous and subcutaneous disin lower dose recipients (two patients), and was usually noted ease after only 1 week of therapy with 400 mg of fluconazole within 3 months of initiating fluconazole therapy. Chapped lips daily; this patient was removed from the study. This patient and dry skin were also seen more commonly in higher dose was successfully treated with amphotericin B followed by itrarecipients (four patients) than in lower doses recipients (one conazole. The fourth patient had stable pulmonary disease but patient). Neurological complaints such as headache and dizziprogressive cutaneous disease after 7 months of therapy with ness were uncommon, and moderate elevation of liver transam-800 mg of fluconazole daily; this patient was successfully inase levels and decreased libido were reported by only one treated with amphotericin B. The patient's compliance with fluconazole therapy was considered questionable. patient each, respectively. Six patients had received prior antifungal therapy for blastomycosis with ketoconazole and/or amphotericin B (range, 1 -18 months) and were included in this trial because of cul- treated. There were similar numbers of patients in each group / 9c38$$au32 07-22-97 07:11:21 cidal UC: CID Discussion reported efficacy of ketoconazole at doses of 400 to 800 mg daily and is better tolerated [1, 2, 14] . Of the three currently available oral antifungal azoles, itraco-As noted in our earlier pilot study [10] , patients for whom nazole has emerged as the most effective agent for the treatment prior antifungal therapy had failed tended to respond to flucoof non-life-threatening, non-CNS blastomycosis [3] [4] [5] . In a renazole therapy. Similarly, in the present study, five of six pacently reported trial [3] , treatment with daily doses of 200 to tients for whom prior therapy with amphotericin B and/or keto-400 mg of itraconazole was successful for 38 (95%) of 40 paconazole had failed were successfully treated with fluconazole. tients with blastomycosis who had received at least 2 months These patients had varied sites of clinical involvement includof therapy. This efficacy is similar to that reported for amphoteriing the skin in three patients and bone, larynx, and lung involvecin B [12, 13] and is somewhat better than that reported for ment in one patient each, respectively. The explanation for this ketoconazole [1, 2] . In addition, itraconazole appears to be better observation remains unclear. Noncompliance leading to failure tolerated than ketoconazole and amphotericin B; it causes fewer of the initial treatment was not apparent in any of these patients. gastrointestinal, hepatic, and endocrinologic toxicities than keto-It is possible that the failure of ketoconazole treatment was conazole [14] and none of the infusion-related toxicities or renal related to inadequate absorption, but no serum levels were and electrolyte disturbances associated with amphotericin B adavailable to document this possibility. Although the pharmacoministration [15] . Thus, even though no comparative trial bekinetics of fluconazole appear to be superior to those of ketocotween different antifungal agents has been performed, reported nazole, data comparing the relative tissue concentrations of data and clinical experience suggest that itraconazole is the oral these two agents are unavailable [8] . antifungal agent of choice for the treatment of most cases of Generally, fluconazole is better tolerated than ketoconazole non-life-threatening blastomycosis [3] [4] [5] . Ketoconazole remains and, unlike ketoconazole, does not require an acid medium for in use largely because it is much less expensive. optimal absorption. In addition, fluconazole has excellent CSF There has been considerably less experience with fluconazole penetration and has been used successfully to treat CNS blastoas treatment of blastomycosis, and the current trial represents mycosis [16, 17] , whereas CNS relapses have been described the largest clinical experience to date. Previously reported results in patients with blastomycosis who received treatment with of a pilot study [10] revealed that the efficacy of fluconazole at ketoconazole [18, 19] . Taken as a whole, these data suggest doses of 200 or 400 mg daily for the treatment of non-lifethat fluconazole is a useful therapeutic agent for patients with threatening blastomycosis was moderate. In that study, eight blastomycosis for whom prior antifungal therapy has failed, (62%) of 13 and seven (70%) of 10 patients receiving 200 mg particularly therapy with ketoconazole. and 400 mg of fluconazole therapy, respectively, were success-Adverse events related to fluconazole therapy were reported fully treated. Fluconazole therapy was well-tolerated; only one by 48% of the patients in this study, although most were minor patient was removed from the study because of toxicity. and only one patient was removed from the study prematurely The present study demonstrates that the efficacy of higher because of a drug toxicity. The group receiving the highest dose doses of fluconazole in the treatment of blastomycosis is very of fluconazole reported almost twice as many adverse events good. Of the 39 evaluable patients, 34 (87%) were successfully (especially dermatologic complaints) as those receiving the lowtreated, and there appeared to be very little difference in reest dose, thus suggesting that higher doses were less well tolersponse between those patients receiving 400 or 800 mg daily. ated. Alopecia, recently described in patients receiving flucona-These findings indicate that higher doses of fluconazole for zole therapy [20] , was seen in 23% of the patients in this study. the treatment of blastomycosis are superior to lower doses of Chapped lips and dry skin were also common. Transient elevafluconazole used in our earlier trial [9] . In the current trial, tion of liver transaminase levels and sexual dysfunction (adverse there were five treatment failures, including treatment for two events that have been more commonly associated with ketoconapatients whose compliance was a significant concern and treatzole therapy [14]) were uncommon. All these toxicities were ment for one patient who was withdrawn from the study only reversible with discontinuation of fluconazole treatment. 7 days after starting therapy because of very aggressive disease.
In summary, fluconazole at daily doses of 400 to 800 mg The other two treatment failures occurred despite good compliappears to be effective therapy for non-life-threatening blastoance as determined by pill counts. mycosis. Fluconazole is at least as efficacious and is better Serum levels of fluconazole were not routinely available to tolerated than ketoconazole. However, at equivalent doses, it determine the adequacy of drug absorption; antifungal susceptiappears to be less effective than itraconazole, but at higher bility testing for B. dermatitidis was not routinely performed, doses, the efficacy of fluconazole approaches that of itraconaas this methodology has not been standardized. Thus, it is zole at 200 to 400 mg daily. On the basis of these data, flucoimpossible to adequately explain these two treatment failures.
nazole should be considered an alternative therapy for patients Nonetheless, our data suggest that the efficacy of fluconazole with blastomycosis and should be given at an initial dosage of at doses of 400 to 800 mg daily for the treatment of blastomycoat least 400 mg daily for a minimum of 6 months. Although sis is similar to that of itraconazole at doses of 200 to 400 mg fluconazole remains a more costly drug than ketoconazole, its daily and is well tolerated. Furthermore, at these doses, the efficacy and tolerability argue that it should be considered as a first therapeutic alternative for patients who cannot tolerate efficacy of fluconazole appears to be equal to or exceeds the / 9c38$$au32 07-22-97 07:11:21 cidal UC: CID / 9c38$$au32 07-22-97 07:11:21 cidal UC: CID
